Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $87.43, but opened at $90.29. Blueprint Medicines shares last traded at $93.42, with a volume of 94,236 shares trading hands.
Wall Street Analyst Weigh In
BPMC has been the subject of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price target on the stock. StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. JMP Securities reissued a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Monday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and an average price target of $122.72.
Check Out Our Latest Research Report on BPMC
Blueprint Medicines Trading Up 18.2 %
The company has a market capitalization of $6.57 billion, a P/E ratio of -48.99 and a beta of 0.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm has a fifty day moving average price of $93.42 and a 200-day moving average price of $95.36.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to analysts' expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company's quarterly revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the company earned ($2.20) earnings per share. On average, equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.
Insider Buying and Selling at Blueprint Medicines
In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the sale, the chief operating officer now directly owns 71,657 shares of the company's stock, valued at $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares of the company's stock, valued at $1,395,822.42. The trade was a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,720 shares of company stock worth $2,177,846 over the last ninety days. 4.21% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Blueprint Medicines
A number of large investors have recently made changes to their positions in BPMC. Quarry LP bought a new position in Blueprint Medicines in the 3rd quarter worth about $32,000. Covestor Ltd boosted its position in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 403 shares during the period. Quantbot Technologies LP purchased a new position in Blueprint Medicines during the third quarter valued at approximately $108,000. Values First Advisors Inc. bought a new stake in Blueprint Medicines during the 3rd quarter worth approximately $122,000. Finally, CWM LLC lifted its stake in Blueprint Medicines by 69.2% in the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 765 shares in the last quarter.
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
